CLINICAL TRIALS PROFILE FOR IBUTILIDE FUMARATE
✉ Email this page to a colleague
All Clinical Trials for IBUTILIDE FUMARATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00589992 ↗ | Ibutilide Administration During Pulmonary Vein Ablation | Unknown status | Abbott Medical Devices | N/A | 2007-10-01 | To test the hypothesis that localized functional reentry maintains Afib in humans, ibutilide will be administered intravenously in patients undergoing an Afib ablation. The hypothesis of this study is that ibutilide will decrease the high frequency signals observed in Afib suggesting the presence of micro reentrant circuits as the basic mechanism of Afib, especially for the paroxysmal Afib group. The potential difference in response to the ibutilide in patients with paroxysmal versus persistent Afib may show the difference in the underlying mechanism of Afib between these two groups. |
| NCT00589992 ↗ | Ibutilide Administration During Pulmonary Vein Ablation | Unknown status | St. Jude Medical | N/A | 2007-10-01 | To test the hypothesis that localized functional reentry maintains Afib in humans, ibutilide will be administered intravenously in patients undergoing an Afib ablation. The hypothesis of this study is that ibutilide will decrease the high frequency signals observed in Afib suggesting the presence of micro reentrant circuits as the basic mechanism of Afib, especially for the paroxysmal Afib group. The potential difference in response to the ibutilide in patients with paroxysmal versus persistent Afib may show the difference in the underlying mechanism of Afib between these two groups. |
| NCT00589992 ↗ | Ibutilide Administration During Pulmonary Vein Ablation | Unknown status | Ball Memorial Hospital | N/A | 2007-10-01 | To test the hypothesis that localized functional reentry maintains Afib in humans, ibutilide will be administered intravenously in patients undergoing an Afib ablation. The hypothesis of this study is that ibutilide will decrease the high frequency signals observed in Afib suggesting the presence of micro reentrant circuits as the basic mechanism of Afib, especially for the paroxysmal Afib group. The potential difference in response to the ibutilide in patients with paroxysmal versus persistent Afib may show the difference in the underlying mechanism of Afib between these two groups. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for IBUTILIDE FUMARATE
Condition Name
Clinical Trial Locations for IBUTILIDE FUMARATE
Trials by Country
Clinical Trial Progress for IBUTILIDE FUMARATE
Clinical Trial Phase
Clinical Trial Sponsors for IBUTILIDE FUMARATE
Sponsor Name
